Molecular Partners
Business Services · Switzerland · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Wagistrasse 14, Schlieren, Zurich, 8952,...Phone Number
+41 447557700Website
www.molecularpartners.comRevenue
$6.2 MillionStock Symbol
MOLNIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Molecular Partners
Molecular Partners AG is a clinical-stage biotech company developing DARPin therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.Explore more
Molecular Partners Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Molecular Partners your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Molecular Partners had a recent Job posting/layoffs
Check out if Molecular Partners is spiking on competitors!
Molecular Partners, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Molecular Partners recently announced quarterly report
Check if Molecular Partners has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Molecular Partners has new funding data
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Molecular Partners
Product Launch: Get notified when Molecular Partners launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Molecular Partners is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Molecular Partners is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Molecular Partners.
Molecular Partners financials insights
Gather financial insights about Molecular Partners, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2007
Series A
$15.6M
2009
Series B
$44.2M
2014
Stock Offering
$108.3M
2016
Share Placement
$31.2M
Molecular Partners Tech Stack
A closer look at the technologies used by Molecular Partners
Most Recent Scoops
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Molecular Partners has entered into an agreement with Orano Med for lead supply, spanning into commercial supply. Additionally, Molecular Partners has signed a development agreement with Eckert & Ziegler for actinium supply focused on early-stage development.
Product Development, Pharmaceuticals
Project
Molecular Partners has completed its first compassionate care program for DLL3, with data presented in South Africa approximately one month ago. The company is now entering Phase I clinical trials with significant learnings from the compassionate care program.
Pharmaceuticals, Clinical Operations
Earnings
Business Finance, Finance, Financial Operations
Molecular Partners News & Media
Molecular Partners to Present at TD Cowen’s 7th Annual Oncology Innovation Summit
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced that members of the management team will participate in the following upcoming investor conference.Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced corporate highlights and unaudited financial results for the first quarter of 2026.Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences
ZURICH-SCHLIEREN, Switzerland and Concord, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics, today announced its attendance and presentations on its lead Radio-DARPin candidate MP0712 at upcoming scientific conferences.Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced the publication of Phase 1 clinical data in Nature Cancer demonstrating the potential of the tumor-localized CD40 agonist, MP0317, to modulate the tumo
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Molecular Partners
Sign Up For FreeTo access detailed company insights
Molecular Partners AG is a clinical-stage biotech company developing DARPin therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of ophthalmology, oncology and infectious... Read More
